AT-56 is primarily used in research settings as a selective inhibitor of soluble epoxide hydrolase (sEH), an enzyme involved in the metabolism of epoxyeicosatrienoic acids (EETs). By inhibiting sEH, AT-56 helps increase the levels of EETs, which have anti-inflammatory, vasodilatory, and organ-protective effects. This makes AT-56 a valuable tool in studying cardiovascular diseases, inflammation, and pain pathways. It has shown potential in preclinical models for reducing neuropathic pain and protecting against ischemia-reperfusion injury. Due to its role in modulating lipid mediators, AT-56 is also used to investigate metabolic and inflammatory conditions, including hypertension and diabetes-related complications. Its application remains confined to laboratory and experimental pharmacology, aiding in the validation of sEH as a therapeutic target.